trending Market Intelligence /marketintelligence/en/news-insights/trending/ndrxlgjxd-uowffzocrwbq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA rejects Amphastar application for asthma inhaler

MI Mobile App

Independent Networks Gain Little Traction On Virtual Multichannel Services

Big Strategy Decisions Ahead For Viacom As It Moves Into The CBS Fold

Street Talk Episode 48 - Bank M&A, Investing Against An Inverted Yield Curve Overview


US FDA rejects Amphastar application for asthma inhaler

The U.S. FDA withheld approval of Amphastar Pharmaceuticals Inc.'s over-the-counter asthma inhaler, Primatene Mist.

The regulator, in a complete response letter, asked the pharmaceutical company to make further changes to the inhaler's label and packaging followed by a study to evaluate patients' ability to use the product without professional guidance.

Amphastar plans to address these concerns by mid-2017.

The original Primatene Mist was discontinued because it contained chlorofluorocarbons, which are harmful to the ozone layer. The new version of the inhaler uses the same active ingredient as the old one but uses a different delivery system.